Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

295

Participants

Timeline

Start Date

August 23, 2017

Primary Completion Date

June 6, 2025

Study Completion Date

August 5, 2025

Conditions
Schizophrenia
Interventions
DRUG

Brexpiprazole

Once daily, oral tablets

Trial Locations (57)

10036

Clinical Research Site #130, New York

11000

Clinical Research Site #500, Belgrade

Clinical Research Site #504, Belgrade

14618

Clinical Research Site #100, Rochester

18000

Clinical Research Site #502, Niš

21000

Clinical Research Site #501, Novi Sad

28501

Clinical Research Site #121, Kinston

29620

Clinical Research Site #224, Torremolinos

30331

Clinical Research Site #136, Atlanta

34000

Clinical Research Site #168, Durango

Clinical Research Site #503, Kragujevac

36013

Clinical Research Site #526, Poltava

36303

Clinical Research Site #101, Dothan

37000

Clinical Research Site #163, León

44100

Clinical Research Site #165, Guadalajara

44125

Clinical Research Site #113, Garfield Heights

45219

Clinical Research Site #133, Cincinnati

46027

Clinical Research Site #525, Ternopil

49027

Clinical Research Site #527, Dnipro

61068

Clinical Research Site #523, Kharkiv

61153

Clinical Research Site #521, Kharkiv

64310

Clinical Research Site #171, Monterrey

64710

Clinical Research Site #160, Monterrey

66160

Clinical Research Site #148, Kansas City

70629

Clinical Research Site #138, Lake Charles

73116

Clinical Research Site #102, Oklahoma City

73488

Clinical Research Site #522, Kherson

74136

Clinical Research Site #135, Tulsa

75034

Clinical Research Site #140, Frisco

78213

Clinical Research Site #170, San Luis Potosí City

79021

Clinical Research Site #520, Lviv

80131

Clinical Research Site #283, Naples

80230

Clinical Research Site #161, Culiacán

89109

Clinical Research Site #124, Las Vegas

90230

Clinical Research Site #105, Culver City

90807

Clinical Research Site #103, Long Beach

92805

Clinical Research Site #128, Anaheim

97070

Clinical Research Site #166, Mérida

98201

Clinical Research Site #108, Everett

127083

Clinical Research Site #545, Moscow

150003

Clinical Research Site #544, Yaroslavl

163530

Clinical Research Site #542, Arkhangelsk

192019

Clinical Research Site #541, Saint Petersburg

197341

Clinical Research Site #540, Saint Petersburg

300329

Clinical Research Site #242, Timișoara

355038

Clinical Research Site #543, Stavropol

400660

Clinical Research Site #241, Cluj-Napoca

06200

Clinical Research Site #321, Nice

55-040

Clinical Research Site #263, Tyniec Mały

15-879

Clinical Research Site #266, Bialystok

80-542

Clinical Research Site #269, Gdansk

60-744

Clinical Research Site #260, Poznan

61-485

Clinical Research Site #272, Poznan

58-309

Clinical Research Site #270, Wałbrzych

54-617

Clinical Research Site #267, Wroclaw

041914

Clinical Research Site #244, Bucharest

IS700282

Clinical Research Site #243, Iași

All Listed Sponsors
collaborator

H. Lundbeck A/S

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT03238326 - Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia | Biotech Hunter | Biotech Hunter